Quick Read – LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. – LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioid-free label claim. – Phase 3 trials…
unching in 2026 with 2027 readouts will test whether Latigo’s Nav1.8 pipeline can replicate Vertex’s suzetrigine success. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and LTGO didn’t make the cut. Grab the names FREE today
Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about. The Thousand Oaks, California, clinical-stage developer priced its IPO at $18 per share and opened at $21, raising nearly $350 million after an oversubscribed book. Shares recently changed hands at $19.38.
That is up 6.2% from the $18.25 close on August 7 and 4.62% higher in the latest session. The Non-Opioid Pain Thesis Latigo is a bet that selective Nav1.8 inhibition can capture a meaningful share of a U.S. pain market estimated at 250 million prescriptions annually. The S-1 describes the company as a “clinical-stage biopharmaceutical focused on non-opioid pain medicines” with three assets: – LTG-001, a Nav1.8 inhibitor for acute pain – LTG-321, a Nav1.8 inhibitor for chronic musculoskeletal pain – LTG-418, a next-generation Nav1.8 inhibitor in preclinical development In a randomized, placebo-controlled abdominoplasty trial in 343 patients across four U.S. centers, high-dose oral LTG-001 hit its primary endpoint with a 62.1-point SPID48 improvement versus placebo and approximately 50% greater analgesic effect than the active hydrocodone/acetaminophen comparator arm.